Viewing Study NCT03940404


Ignite Creation Date: 2025-12-24 @ 7:58 PM
Ignite Modification Date: 2026-01-28 @ 2:30 PM
Study NCT ID: NCT03940404
Status: UNKNOWN
Last Update Posted: 2019-05-07
First Post: 2019-04-27
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Anlotinib Therapy in Patients With Advanced Lung Cancer.
Sponsor: First People's Hospital of Hangzhou
Organization:

Study Overview

Official Title: Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
Status: UNKNOWN
Status Verified Date: 2019-05
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world.

Subjects of the study: advanced Lung cancer.

Methods of the study:

This is a real world, prospective, Non-Interventional, Follow-up registration study.

Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle.

End point:

Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: